SBIR/STTR Research Award

IPformatics: An Integrated Knowledgebase of Patent Claims and Genomic Data

Award identifier 4dad65ceaf398da9476b946731820951372bda238ac568481f38bd2bc366f140Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$138,591

Program and phase

SBIR · Phase I

Award year

2006

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
BIOSPHEREX, LLC
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
PHS2006-2
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): This is a proposal to create a knowledgebase of the intellectual property rights that exist in human genes. When completed, the knowledgebase will have three distinct elements: (1) a searchable sequence component that contains nucleotide and amino sequences listed in U.S. Patents; (2) a gene patent component that links each human gene with the U.S. patents which claim it; and (3) a claim annotation component that contains information about the claim and the subject matter it covers. An aim of the knowledgebase is to simplify gene patent searching and analysis. Amino acid and nucleotide searching will not be required to identify which genes are covered by U.S. patents. Instead, gene names and accession numbers will be directly linked to patented sequences, enabling instant access to patent information. At a glance, users will be able to determine which genes are covered by patents, and the extent to which the human genome is owned. A second aim is provide information about whether a gene is "claimed" in a patent. Only when a gene is claimed does the patent owner possess the right to exclude others from using it. The knowledgebase will identify the patents which confer rights in the gene, rather than those which only disclose it. Finally, a long-term aim is annotate and classify patent claims, enabling users to understand the nature of the patent rights. Patent claims can extend to a gene as a composition of matter, but can also be restricted to the use of the gene. Within each class, there are varying scopes of coverage. To manually classify claims would be a gargantuan task since there are over 56,000 U.S. patents which relate to nucleic acids. Text- mining algorithms will be devised that will automatically parse and classify gene patent claims. The information provided in the knowledgebase will be a tool to understand the impact of patents on the provision of healthcare. Opponents of gene patents have argued that patents restrict access, drive up healthcare costs, and put private property interests ahead of societal concerns. The knowledgebase will provide a way to readily identify the patent protection on human biologies and underlying technologies, and then to monitor how the various classes of patent protection effect pricing, competition, and other economic indicators. It will also have commercial value to the biotechnology industry as a resource to readily determine the patent rights that exist in human genes when developing new products and research initiatives.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.